China (Mainland)
Premiumsupplier
Bortezomib Manufacturer 179324-69-7 Treatment Of Cancer Drugs CAS NO.179324-69-7
- Min.Order: 10 Gram
- Payment Terms: T/T,
- Product Details
Keywords
- 99% Bortezomib
- Bortezomib Manufacturer
- Treatment Of Cancer Drugs
Quick Details
- ProName: Bortezomib Manufacturer 179324-69-7 Tr...
- CasNo: 179324-69-7
- Molecular Formula: C19H25BN4O4
- Appearance: White Powder
- Application: It Can Be Used As Pharmaceutical Inte...
- DeliveryTime: 2-4 days after confirming your payment...
- PackAge: 100g/ bag, 2 kg/ bag, 25kg/ carton or ...
- Port: Wuhan
- ProductionCapacity: 10000 Metric Ton/Month
- Purity: 99%
- Storage: Store in sealed containers at cool & d...
- Transportation: By DHL, TNT, FedEx, HKEMS, UPS, Etc
- LimitNum: 10 Gram
Superiority
Advantages:
Hubei XinRunde Chemical Co., Ltd is a renowned pharmaceutical manufacturer. We can offer high quality products at competitive price in quick delivery with 100% custom pass guaranteed. Never stop striving to offer our best service is our philosophy. We have Flexible and Untraceable payment terms. As a leading manufacture, our products have been exported to Germany, Norway, Poland, Finland, Spain, UK, France, Russia, USA, Brazil, Mexico, Australia, Japan, Korea, Thailand, Indonesia, Uruguay and many other countries.
1. Quality.Every batch of steroid powders have tobetested by our QC(quality control) before they are allowed to sell.
2. Delivery We have stock, so we can delivery quickly at the very day when receive the payment. Within 24 hours after receiving the payment Lead time 4 or 7 days.
3. Discreet package Safelyand Professionally Disguised Package Guaranteed. For your safety and to insure delivery all products will be packed in a discreet way to prevent any suspicions, no steroids related name will appear on the parcels. high successful delivery rate.
4. Warm after-sale service Any of your question would be solved for the first as soon as possible.
Details
| Bortezomib Basic information |
| Product Name: | Bortezomib |
| Synonyms: | Boronic acid, B-[(1R)-3-Methyl-1-[[(2S)-1-oxo-3-phenyl-2-[(2-pyrazinylcarbonyl)aMino]propyl]aMino]bu;MG-341 PS-341;BortezoMib Base;BortezoMib-D8;bortezoMib(other);MLM341;BortezoMib R;BortezoMib (PS-341, LDP-341, MLM341) |
| CAS: | 179324-69-7 |
| MF: | C19H25BN4O4 |
| MW: | 384.24 |
| EINECS: | 1308068-626-2 |
| Product Categories: | ProteasomeInhibitors;Apis;Inhibitor;Final material;API;peptides;Boron Derivatives;Inhibitors;Intermediates & Fine Chemicals;Pharmaceuticals;Pepetides |
| Mol File: | 179324-69-7.mol |
|
|
|
| Bortezomib Chemical Properties |
| Melting point | 122-124°C |
| density | 1.214 |
| RTECS | ED7771666 |
| storage temp. | Hygroscopic, -20°C Freezer, Under Inert Atmosphere |
| solubility | Soluble in chloroform, dimethyl sulfoxide, ethanol and methanol. |
| Stability: | Hygroscopic and Moisture Sensitive |
| CAS DataBase Reference | 179324-69-7(CAS DataBase Reference) |
| Safety Information |
| Risk Statements | 23/24/25-48/23/24/25 |
| Safety Statements | 9-27-36/37-45-60 |
| HazardClass | 6.1 |
| Hazardous Substances Data | 179324-69-7(Hazardous Substances Data) |
| Bortezomib Usage And Synthesis |
| Description | Bortezomib, a modified dipeptidyl boronic acid, is a therapeutic proteasome inhibitors used for the treatment of cancers. It is indicated for the treatment of relapsed multiple myeloma and mantle cell lymphoma. It is capable of inhibiting the mammalian 26S proteasome, which is important in regulating the intracellular concentration of specific proteins to maintain homeostasis within cells. The disruption of 26S proteasome function disrupts normal cellular homeostasis, leading to cytotoxic effect on various kinds of cancer cells. |
| Drug for Cancer treatment |
Bortezomib is a drug for treatment of hematopoietic malignancies with the appearance being white or white-like crystalline powder. It is easily soluble in dimethyl sulfoxide, ethanol, but insoluble in aqueous solution. This product is the reversible inhibitor of the mammal cell 26S proteasome chymotrypsin-like activity. 26S proteasome is a large protein complex which can degrade ubiquitin. Ubiquitin proteasome pathway plays an important role in regulation of the intracellular concentration of specific proteins in order to maintain the stability of the intracellular environment. Proteolytic affects intracellular multi-level signalling cascade. The disruption of the normal intracellular environment can lead to cell death while the inhibition of the 26S proteasome can prevent the hydrolysis of specific proteins. In vitro tests have proved bortezomib exhibits cytotoxicity to multiple types of cancer cells. The in vivo models of preclinical tumor have proved that bortezomib is capable of delaying the tumor growth of multiple myeloma which is suitable for the treatment of multiple myeloma. The above information is edited by the Chemicalbook of Dai Xiongfeng. |
| Chemical Properties | Yellow Solid |
| Uses | Bortezomib is the first proteasome inhibitor to be approved b the US FDA for multiple myeloma, a blood cancer. A reversible inhibitor of the 26S proteasome-a barrel-shaped multiprotein particle found in the nucleus and cytosol of all eukaryotic cells. T |
| Definition | ChEBI: L-Phenylalaninamide substituted at the amide nitrogen by a 1-(dihydroxyboranyl)-3-methylbutyl group and at Nalpha by a pyrazin-2-ylcarbonyl group. It is a dipeptidyl boronic acid tha reversibly inhibits the 26S proteasome. |